Department of Nutrition and Health Sciences, University of Nebraska-Lincoln, Lincoln, Nebraska, USA.
Nutr Rev. 2018 Aug 1;76(8):618-638. doi: 10.1093/nutrit/nuy021.
Inflammatory bowel disease (IBD) is a chronic, inflammatory condition of the gastrointestinal tract. Patients with IBD present with debilitating symptoms that alter the quality of life and can develop into severe complications requiring surgery. Epidemiological evidence indicates Westernized societies have an elevated IBD burden when compared with Asian societies. Considering the stark contrast between the typical Western and Eastern dietary patterns, it is postulated that differences in food and lifestyle contribute to lower IBD incidence in Asian countries. Soybeans (Glycine max), which are consumed in high quantities and as various preparations in Eastern societies, contain a wealth of natural, biologically active compounds that include isoflavones, bioactive peptides, protease inhibitors, and phytosterols, among many others. These compounds have been shown to improve human health, and preclinical evidence suggests they have potential to improve the prognosis of IBD. This review summarizes the current state of evidence regarding the effects and the mechanisms of action of these soybean-derived bioactive compounds in experimental models of IBD.
炎症性肠病（IBD）是一种慢性、炎症性胃肠道疾病。IBD 患者会出现使生活质量恶化的衰弱症状，并可能发展成需要手术的严重并发症。流行病学证据表明，与亚洲社会相比，西方社会的 IBD 负担更高。考虑到典型的西方和东方饮食模式之间的明显差异，有人推测，食物和生活方式的差异导致亚洲国家的 IBD 发病率较低。大豆（Glycine max）在东方社会中大量食用，并以各种形式的制剂食用，含有丰富的天然、生物活性化合物，包括异黄酮、生物活性肽、蛋白酶抑制剂和植物固醇等。这些化合物已被证明有益于人类健康，临床前证据表明它们有可能改善 IBD 的预后。本综述总结了目前关于这些大豆生物活性化合物在 IBD 实验模型中的作用及其作用机制的证据状况。
